An emerging urine test has proved to be more accurate than conventional methods in detecting bladder and prostate cancers, ...

Five hospitals in England and Wales have switched to urine test, rather than invasive hospital procedure ...

Researchers from the University of Birmingham's Bladder Cancer Research Center have used a new method to detect chemical changes in the DNA in an individual's urine sample; epigenetic changes, called ...

A high percentage of bladder cancers can be cured if they are found early. Once cancer spreads outside the bladder, it is much harder to treat. That’s why it’s important to first bring up any ...

Bladder cancer arises from the lining of the bladder, the organ that stores urine, and is one of the most common cancers in the United States. Most patients are diagnosed at an early stage called ...

Fox Chase Cancer Center researchers reported positive results from the trial, known as RETAIN-2, demonstrating that a response-adapted bladder-preservation approach involving neoadjuvant ...

Marks the first Medicare coverage decision for Veracyte’s whole-genome sequencing-based TrueMRD platform and launch of the first test Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics ...

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the cancer benefit from immunotherapy with atezolizumab compared to placebo whereas ...

OSLO, Norway, June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The ...

In a multi-institutional study published in Science Direct, researchers revealed that testing urine-based tumor DNA (utDNA) can help predict which bladder cancer patients are at higher risk for ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...